同时检测新型癌症药物的剂量,有或没有第二种药物
Nolan A Wages1,2, Ramy R Saleh3, Thomas M Braun4
1Department of Biostatistics, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Journal of clinical and translational science
|June 14, 2023
概括
本研究引入了一种适应性临床试验设计,使用持续重新评估方法转移模型来确定Agent A的最大耐受剂量 (MTD),一种新的癌症疗法,单独和与抗PD-1药物一起.
科学领域:
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
- 药理学 药理学 是一个学科.
背景情况:
- 早期瘤学试验面临复杂的研究问题,需要创新的设计.
- 评估新型药物,如造血原体基因酶-1抑制剂 (Agent A) 需要量身定制的研究策略.
- 组合疗法,如Agent A与抗PD-1药物,在晚期恶性瘤中越来越重要.
研究的目的:
- 提出和评估一项新的I期临床试验设计.
- 同时确定Agent A作为单一药物和与抗PD-1药物结合的最大耐受剂量 (MTD).
- 展示适应性设计在满足当代瘤学研究目标方面的灵活性.
主要方法:
- 应用持续重新评估方法转移模型用于剂量升级.
- 同时评估Agent A单一治疗和与抗PD-1药物的联合治疗.
- 模拟研究,以评估拟议的自适应设计的操作特性.
主要成果:
- 持续重新评估方法转移模型成功应用于拟议的第一阶段试验设计.
- 模拟证明了自适应设计的可行性和操作特性.
- 该设计允许同时确定Agent A的剂量,包括和没有抗PD-1治疗.
结论:
- 适应性设计为复杂的瘤学试验目标提供了灵活性.
- 描述的方法适用于其他并发单疗法和与二元安全终点结合的组合研究.
- 这项工作强调了新的设计应用,以促进未来的创新试验实施.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.0K
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
8.7K
相关概念视频
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Crossover Experiments
2.9K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.9K
